Skip to main content

Table 5 Multivariate analysis of variables correlated with the treatment regimen status and other significant prognostic factors in 730 eligible cases

From: The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis

 DMFSLRFSPFSOS
BHR(95%CI)PBHR (95%CI)PBHR (95%CI)PBHR (95%CI)P
Gender
 Female1  1  1  1  
 Male−0.9340.393 (0.188–0.823)0.0130.2471.280 (0.733–2.237)0.385−0.2050.815 (0.549–1.210)0.310−0.5230.592 (0.347–1.011)0.055
Age
 <441  1  1  1  
  ≥ 44−0.0960.909 (0.582–1.421)0.675−0.4390.645 (0.393–1.058)0.082−0.2560.774 (0.571–1.050)0.100−0.2520.777 (0.534–1.132)0.189
Tumor stage
 T11  1  1  1  
 T20.1491.161 (0.335–4.026)0.814−0.2290.795 (0.113–5.603)0.818−0.2000.819 (0.287–2.339)0.7090.2061.229 (0.407–3.714)0.715
 T3−0.8940.409 (0.128–1.305)0.1310.1091.116 (0.246–5.065)0.887−0.5100.600 (0.256–1.405)0.240−0.5460.580 (0.215–1.561)0.280
 T4−0.4740.623 (0.248–1.562)0.313−0.3290.720(0.175–2.954)0.648−0.6640.515 (0.243–1.091)0.083−0.6320.531 (0.231–1.223)0.137
Node stage
 N01  1  1  1  
 N1−1.9790.138 (0.046–0.418)< 0.001−1.4370.238 (0.047–1.210)0.083−1.6030.201 (0.088–0.458)< 0.001−1.5090.221 (0.086–0.567)0.002
 N2−2.2510.105 (0.043–0.260)< 0.001−0.5940.552 (0.160–1.902)0.347−1.3290.265 (0.138–0.508)< 0.001−1.2420.289 (0.141–0.594)0.001
 N3−1.3300.264 (0.111–0.629)0.003−0.3290.720(0.204–2.542)0.609−0.8760.416 (0.216–0.804)0.009−0.8000.449 (0.216–0.934)0.032
Clinical stage
 III1  1  1  1  
 IV0.2241.251 (0.436–3.593)0.677−0.0520.950 (0.212–4.254)0.9460.0801.083 (0.482–2.434)0.847−0.4480.639 (0.256–1.598)0.338
Target therapy
 Without1  1  1  1  
 With0.8402.317 (1.224–4.384)0.010−0.3390.712 (0.427–1.189)0.1940.3531.423 (0.985–2.058)0.0600.7542.125 (1.269–3.560)0.004
Induction chemotherapy
 No1  1  1  1  
 Yes0.3031.354 (0.849–2.159)0.203−0.2090.811 (0.471–1.398)0.4510.0311.031 (0.742–1.434)0.855−0.0120.988 (0.655–1.490)0.955